To wrap up this year's author podcast series, The American Journal of Managed Care® speaks with Angela Liu, PhD, MPH, ...
CKD complicates cancer treatment, reducing adjuvant chemotherapy use and increasing mortality risk, necessitating ...
Soefje also discusses the growing role of pharmacists, technology, and comparative efficacy data in improving adherence, ...
At ASH 2025, sonrotoclax demonstrated encouraging response rates and a favorable safety profile as a single-agent BCL2 ...
Sonrotoclax demonstrated a total overall response rate of 52%, including a complete response rate of 16%. However, Wang ...
Key challenges include logistical hurdles, such as the need for specialized training and infrastructure, and financial ...
Highlights of the conference coverage from the 2025 European Society of Medical Oncology (ESMO) Congress included content on ...
Managed care organizations must prioritize dextromethorphan-bupropion based on sustained efficacy, improved remission rates, ...
Intravenous (IV) and subcutaneous (SC) formulations each play important roles in modern oncology care, with distinct ...
Our top 5 heart failure articles of 2025 include FDA approvals, improving guideline-directed medical therapy (GDMT), markers of progressive heart failure (HF) such as findings from echocardiogram ...
The FDA has granted approval to a subcutaneous formulation of mosunetuzumab (Lunsumio VELO; Genentech/Roche) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma ...
The FDA approved oral semaglutide (Wegovy) for weight loss and reducing major adverse cardiovascular events. Novo Nordisk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback